查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1598389

治疗性疫苗市场：按疫苗类型、适应症、给药方法、最终用户划分 - 2025-2030 年全球预测

Therapeutic Vaccines Market by Vaccines Type (Auto-Immune Diseases Vaccines, Chronic Disease Vaccines, Infectious Diseases Vaccines), Disease Indication (Dengue, DTP, Hepatitis), Administration, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年治疗性疫苗市场估值为300.8亿美元，预计到2024年将达到330.5亿美元，复合年增长率为10.35%，到2030年将达到599.5亿美元。

治疗性疫苗是医疗保健产业的一个变革部分，与传统疫苗不同，治疗性疫苗旨在治疗现有疾病，而不是预防疾病。它的工作原理是利用人体的免疫反应来瞄准并消除特定的病原体或癌细胞。治疗性疫苗的需求源于对癌症、自体免疫疾病和感染疾病等慢性和危及生命的疾病进行更有效和更有针对性的治疗的需要。这些疫苗可应用于癌症、感染疾病和各种慢性疾病，最终用户包括医疗保健提供者、研究机构和製药公司。由于生物技术的进步、研发投资的增加以及全球慢性病发病率的上升，预计治疗性疫苗市场将大幅成长。个人化医疗、生物製药的扩散以及人工智慧和机器学习在疫苗开发中的整合等因素正在为创新和进步创造肥沃的土壤。该市场的新机会包括探索新的疫苗配方、联合治疗以及扩大对其他挑战性疾病的适用性。然而，高昂的开发成本、严格的监管障碍以及高定价导致的市场渗透率有限等挑战正在影响市场成长。此外，製造复杂性和安全性问题是临床试验的主要瓶颈。为了促进创新和业务成长，应重点关注次世代定序、生物标记发现和新佐剂技术的开发。重要的是要注重合作伙伴关係关係，以加速研究和开发、简化监管流程以及增加政府和非政府组织的资金筹措。整体而言，市场发展迅速，竞争格局激烈。能够有效应对现有挑战并适应技术变革的公司将拥有明显的优势和巨大的成长潜力。

主要市场统计
基准年[2023] 300.8亿美元
预测年份 [2024] 330.5亿美元
预测年份 [2030] 599.5亿美元
复合年增长率（%） 10.35%

市场动态：快速发展的治疗性疫苗市场的关键市场洞察

供需的动态交互作用正在改变治疗性疫苗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 慢性病、感染疾病等疾病盛行率上升
    • 对标靶疾病的生技药品和药物的需求不断增加
    • 政府增加疫苗研发资金
  • 市场限制因素
    • 与治疗性疫苗相关的副作用
    • 关于疫苗核准的严格政府法规
  • 市场机会
    • 政府和私人组织越来越多地倡议来促进疫苗接种
    • 介绍基于胜肽的治疗性疫苗和肺炎球菌疫苗等新疫苗
    • 活性化研发活动和正在进行中的疫苗开发
  • 市场挑战
    • 疫苗生产临床试验的延误
    • 开发治疗性疫苗的高成本

波特的五力战略工具驾驭治疗性疫苗市场

波特的五力框架是了解治疗性疫苗市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解治疗性疫苗市场的外部影响

外部宏观环境因素在塑造治疗性疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解治疗性疫苗市场的竞争状况

对治疗性疫苗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵治疗疫苗市场供应商的绩效评估

FPNV定位矩阵是评估治疗性疫苗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了治疗性疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对治疗性疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病、感染疾病等疾病发生率增加
      • 针对目标疾病的生技药品和药物的需求增加
      • 政府增加疫苗研发资金
    • 抑制因素
      • 与治疗性疫苗相关的副作用
      • 政府对疫苗核准有严格规定
    • 机会
      • 政府和私人组织正在加强促进疫苗接种。
      • 介绍基于胜肽的治疗性疫苗和肺炎球菌疫苗等新疫苗
      • 增加研发活动和正在进行的疫苗开发
    • 任务
      • 一些疫苗生产的临床试验进展缓慢
      • 开发治疗性疫苗的高成本
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 依疫苗类型分類的治疗性疫苗市场

  • 自体免疫疾病疫苗
  • 慢性病疫苗
  • 感染疾病疫苗
  • 神经系统疾病疫苗

第七章 治疗性疫苗市场：依疾病适应症

  • 登革热
  • DTP
  • 肝炎
  • 人类乳突病毒
  • 流感
  • 病菌感染感染
  • MMR
  • 肺炎链球菌感染
  • 脊髓灰质炎
  • 水痘

第八章治疗性疫苗市场的管理

  • 肌肉内和皮下给药
  • 口服给药

第九章 治疗性疫苗市场：依最终使用者分类

  • 成人
  • 小儿科

第10章美洲治疗性疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太治疗疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的治疗性疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AFFiRiS AG
  • Agenus Inc.
  • Argos Therapeutics Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Celldex Therapeutics, Inc.
  • CSL Limited
  • Emergent Biosolutions, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
Product Code: MRR-030298DFF753

The Therapeutic Vaccines Market was valued at USD 30.08 billion in 2023, expected to reach USD 33.05 billion in 2024, and is projected to grow at a CAGR of 10.35%, to USD 59.95 billion by 2030.

Therapeutic vaccines represent a transformative segment in the healthcare industry, designed to treat existing diseases rather than prevent them, unlike traditional vaccines. They function by harnessing the body's immune response to target and eliminate specific pathogens or cancerous cells. The necessity for therapeutic vaccines arises from the need for more effective and targeted treatments for chronic and life-threatening diseases such as cancer, autoimmune disorders, and infectious diseases where traditional therapeutic approaches prove inadequate or detrimental. These vaccines find applications across oncology, infectious diseases, and various chronic conditions, with end-users spanning healthcare providers, research organizations, and pharmaceutical companies. The market for therapeutic vaccines is poised for significant growth, driven by advancements in biotechnology, increasing research and development investments, and rising incidences of chronic diseases globally. Factors such as personalized medicine, the proliferation of biopharmaceuticals, and the integration of AI and machine learning in vaccine development create a fertile ground for innovation and progress. Emerging opportunities in the market include exploring new vaccine formulations, combination therapies, and expanding the application scope to other challenging diseases. However, challenges such as high developmental costs, stringent regulatory hurdles, and limited market penetration due to high pricing affect market growth. Additionally, manufacturing complexities and safety concerns in clinical trials pose significant bottlenecks. To foster innovation and business growth, focus should be directed towards next-generation sequencing, biomarker discovery, and the development of new adjuvant technologies. A strong emphasis on collaborative partnerships for accelerated R&D, streamlined regulatory processes, and increased funding from governmental and non-governmental entities will be critical. Overall, the market is characterized by rapid advancements and a competitive landscape. Companies that can adapt to technological changes while effectively navigating the existing challenges will have a distinctive edge and significant growth potential.

KEY MARKET STATISTICS
Base Year [2023] USD 30.08 billion
Estimated Year [2024] USD 33.05 billion
Forecast Year [2030] USD 59.95 billion
CAGR (%) 10.35%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Therapeutic Vaccines Market

The Therapeutic Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence rate of diseases such as chronic and infectious diseases
    • Rising demand for biologics and drugs for targeted diseases
    • Growing government funding for vaccine development
  • Market Restraints
    • Side effects associated with therapeutic vaccines
    • Stringent government regulations for the approval of vaccines
  • Market Opportunities
    • Growing initiatives from government and private organizations to advance vaccination
    • Introduction of novel vaccines such as peptide-based therapeutic vaccines, and pneumococcal vaccines
    • Rising R&D activities and vaccines developments in the pipeline
  • Market Challenges
    • Slow processing of clinical trials for the production of some vaccine
    • High cost associated with the development of the therapeutic vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Therapeutic Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Therapeutic Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Therapeutic Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Therapeutic Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Therapeutic Vaccines Market

A detailed market share analysis in the Therapeutic Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Therapeutic Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Therapeutic Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Therapeutic Vaccines Market

A strategic analysis of the Therapeutic Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic Vaccines Market, highlighting leading vendors and their innovative profiles. These include AFFiRiS AG, Agenus Inc., Argos Therapeutics Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bavarian Nordic A/S, Celldex Therapeutics, Inc., CSL Limited, Emergent Biosolutions, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., and Serum Institute of India Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Therapeutic Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Vaccines Type, market is studied across Auto-Immune Diseases Vaccines, Chronic Disease Vaccines, Infectious Diseases Vaccines, and Neurological Disease Vaccines.
  • Based on Disease Indication, market is studied across Dengue, DTP, Hepatitis, Human Papilloma Virus, Influenza, Meningococcal Disease, MMR, Pneumococcal Disease, Polio, and Varicella.
  • Based on Administration, market is studied across Intramuscular & Subcutaneous Administration and Oral Administration.
  • Based on End-User, market is studied across Adults and Pediatrics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence rate of diseases such as chronic and infectious diseases
      • 5.1.1.2. Rising demand for biologics and drugs for targeted diseases
      • 5.1.1.3. Growing government funding for vaccine development
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with therapeutic vaccines
      • 5.1.2.2. Stringent government regulations for the approval of vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing initiatives from government and private organizations to advance vaccination
      • 5.1.3.2. Introduction of novel vaccines such as peptide-based therapeutic vaccines, and pneumococcal vaccines
      • 5.1.3.3. Rising R&D activities and vaccines developments in the pipeline
    • 5.1.4. Challenges
      • 5.1.4.1. Slow processing of clinical trials for the production of some vaccine
      • 5.1.4.2. High cost associated with the development of the therapeutic vaccines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Therapeutic Vaccines Market, by Vaccines Type

  • 6.1. Introduction
  • 6.2. Auto-Immune Diseases Vaccines
  • 6.3. Chronic Disease Vaccines
  • 6.4. Infectious Diseases Vaccines
  • 6.5. Neurological Disease Vaccines

7. Therapeutic Vaccines Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Dengue
  • 7.3. DTP
  • 7.4. Hepatitis
  • 7.5. Human Papilloma Virus
  • 7.6. Influenza
  • 7.7. Meningococcal Disease
  • 7.8. MMR
  • 7.9. Pneumococcal Disease
  • 7.10. Polio
  • 7.11. Varicella

8. Therapeutic Vaccines Market, by Administration

  • 8.1. Introduction
  • 8.2. Intramuscular & Subcutaneous Administration
  • 8.3. Oral Administration

9. Therapeutic Vaccines Market, by End-User

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Pediatrics

10. Americas Therapeutic Vaccines Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Therapeutic Vaccines Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Therapeutic Vaccines Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AFFiRiS AG
  • 2. Agenus Inc.
  • 3. Argos Therapeutics Inc.
  • 4. Astellas Pharma, Inc.
  • 5. AstraZeneca PLC
  • 6. Bavarian Nordic A/S
  • 7. Celldex Therapeutics, Inc.
  • 8. CSL Limited
  • 9. Emergent Biosolutions, Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Johnson & Johnson Services, Inc.
  • 12. Merck & Co., Inc.
  • 13. Pfizer, Inc.
  • 14. Sanofi S.A.
  • 15. Serum Institute of India Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. THERAPEUTIC VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. THERAPEUTIC VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THERAPEUTIC VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THERAPEUTIC VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTO-IMMUNE DISEASES VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CHRONIC DISEASE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISEASE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENGUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HUMAN PAPILLOMA VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MMR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 198. THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2023